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Introduction
Kang and colleagues, in a recent issue of Cancer Cell,
identified genes that promote breast carcinoma metasta-
sis to bone [1]. Transcriptomes were compared between
the parental MDA-MB-231 human breast carcinoma cell
line and a variant selected one time in vivo for bone colo-
nization from MDA-MB-231 (231-bone). They identified
43 overexpressed genes and 59 underexpressed genes.
This pattern is referred to as a ‘bone metastasis signature’.
Among the overexpressed genes were matrix metallopro-
teinase 1, IL-11, a chemokine receptor for SDF-1
(CXCR4) and connective tissue-derived growth factor.
Cotransfection of gene combinations into the parental
MDA-MB-231 human breast carcinoma cell line resulted
in populations as efficient at bone colonization as 231-
bone, whereas transfection of individual cDNAs modestly
increased the bone metastatic efficiency. Additionally, and
importantly, Kang and colleagues demonstrated that bone
colonizing clones pre-existed within the parental popula-
tions by single cell cloning.
Their results provide insights into the underlying mecha-
nisms of cancer metastasis as well as support for Paget’s
‘seed and soil’ hypothesis [2] regarding organotropism of
metastases at molecular and functional levels. The find-
ings of Kang and colleagues also contribute to the resolu-
tion of recent discussions regarding whether metastasis
competent cells are rare variants or are prevalent within
primary tumors. Furthermore, the findings support asser-
tions that there are genes that specifically contribute to
metastasis.
Microarrays as molecular pathology tools
Expression microarrays have the potential to revolutionize
the practice of pathology by providing a molecular ‘signa-
ture’ that is characteristic of the cancer subtype [3,4].
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Abstract
Using a microarray approach, Kang and colleagues identified several genes involved in the generation
of breast cancer metastasis in bone and demonstrated their roles in bone colonization in vivo. Their
findings and interpretations are reviewed in the context of recent array studies that compared gene
expression in primary tumors and metastases. RNA expression array results have already demonstrated
value in predicting whether metastases will develop in patients. They have also shown that expression
patterns are similar in primary tumors and metastases. The latter data have invited re-examination of
long-held notions related to mechanisms of metastasis. While the arrays show promise for improving
diagnostic capability in breast cancers, ascribing mechanistic interpretations to correlative data should
be done with extreme caution. Kang and colleagues’ paper in Cancer Cell elegantly reinforces the
concepts that efficiency of the metastatic process is dependent on the coordinated expression of
multiple genes and that the expression of metastasis-associated genes is sometimes dependent on the
microenvironment in which cells find themselves.
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Van’t Veer and colleagues used a 70-gene set to identify
and define a ‘poor prognosis’ transcriptome in breast
cancer [5], which was subsequently used to predict the
likelihood of metastasis development and patient survival
[6]. One can envision a scenario whereby pharmaco-
genomic assays will stratify patients needing aggressive
treatment (i.e. metastasis predisposed) versus less
aggressive treatment (i.e. unlikely to develop microscopic
metastases) [7]. Results from the Cancer Cell article
further imply that arrays might further predict where metas-
tases will develop. If so, therapy could be targeted to sites
where metastases are possible, rather than simply admin-
istering toxins systemically.
Metastatic cells in the primary tumor: rare or
predominant?
Microarray data have also been used to challenge long-
held notions that metastases arise from a rare subset of
cells within a primary tumor [5,6,8,9]. It is important,
however, to consider the methodologies used and the
interpretations that arise from the findings represented.
Ramaswamy and colleagues, who compared primary
tumors and metastases from multiple tumor types, found
the array patterns to be nearly identical [8], leading them
and other workers [5,9–11] to infer that metastatic poten-
tial is hardwired into tumor cells. As with the data of Van’t
Veer and colleagues, the microarrays were performed
using bulk measurements (i.e. samples contained mixtures
of RNA from multiple tumor cells). The samples were also
‘contaminated’ with normal stromal cells.
The conclusions, that a predominance of neoplastic cells
had already acquired metastatic potential and that meta-
stases arose from early oncogenic changes rather than
specific events that control metastasis [9], can be chal-
lenged on the basis of other data. In short, while microarray
differences are predictive of patient outcome, they neither
address the issue of metastasis-competent cell prevalence
[12,13] nor do they preclude the existence of metastasis-
controlling genes. Likewise, microarray data cannot distin-
guish contributions from noncancer cells since the starting
materials were not purely neoplastic cells.
Most tumors are clonal in origin, yet are heterogeneous for
multiple phenotypes at diagnosis. Generation of hetero-
geneity is the result of genetic instability that, in turn, leads
to variants with differences in metastatic potential, as
demonstrated by selection of metastatic subpopulations
within a tumor [12]. If one invokes the principles of Luria
and Delbrück [14], the prevalence of metastatic cells
within a tumor would depend on the time at which the
metastatic cells emerged (i.e. earlier in progression would
yield a higher proportion). While reasonable, this simple
notion is complicated by the multistep nature of metasta-
sis. Finely choreographed expression (increased or
decreased) of multiple genes is required for metastatic
competence. In addition, expression changes in tumor
cells are superimposed by tumor cell interactions with the
host microenvironment at virtually every step. If a cell is
(rendered) incapable of completing any step, it is non-
metastatic. In other words, every step of the metastatic
cascade is rate limiting. As a result, it is not surprising that
metastasis is highly inefficient [15]. Metastatic inefficiency
is a critical parameter with regard to interpreting the
microarray results for mechanistic insights.
Butler and Gullino, for example, showed that
(1–4)×106 cells/g tumor per day are shed into the vascu-
lature [16]. Shedding of cells from a primary tumor is only
one step of the metastatic cascade, and the data from
Butler and Gullino would argue that a substantial fraction
of neoplastic cells have this ability. The ability of dissemi-
nated cells to complete subsequent steps in the metastatic
cascade is not inherent a priori, however, as would be
inferred by the relative infrequency of overt metastases.
The issue of colonization is not addressed by any of the
microarray data. It is known that most metastases are
clonal in origin [17]; addressing the issue of metastasis
genes therefore requires direct comparison of primary cells
and multiple metastases. It is probable that many tumors
contain subpopulations that have accumulated some, but
not all, of a metastasis signature. When a tumor has a suffi-
cient proportion of cells that express at least one of the
‘poor prognosis’ genes, it follows that it has increased like-
lihood for cells coexpressing the entire complement of
metastasis-associated genes. Unfortunately, bulk array
data (i.e. cells are not microdissected) cannot discern
whether the appropriate pattern of expression exists within
individual cells versus within the entire population.
The data from Kang and colleagues illustrate this argu-
ment elegantly. Several single cell clones showed differen-
tial expression of one or more of the bone metastasis
profile genes; however, only a small fraction showed coor-
dinate expression. Likewise, transfection of osteopontin or
IL-11 alone resulted in only a modest increase in bone col-
onization efficiency. However, cotransfection of these
genes (and others described earlier) resulted in higher
metastatic efficiency. In other words, osteopontin and
IL-11 were not sufficient for bone colonization. Of course,
interpretation must be done with caution since there was
already a baseline of 30% colonization in bone (i.e. what
other genes were ‘on’ or ‘off’ already?).
This issue raises an important point that limits all experi-
mental metastasis studies with current technology and
reagents; virtually all human breast cancer cell lines were
derived from metastases. Baseline measurements will be
skewed as a result, but the magnitude of bias is not
known. In the context of bone metastasis, it is likewise
important to note that none of the commonly used human
breast carcinoma cell lines were derived from bone metas-63
tases (i.e. most, including MDA-MB-231, were isolated
from pleural effusions). Finally, interpretation is always
complicated by the artificial nature of intracardiac injection
models since none of the current human breast carcinoma
cell lines colonize bone from an orthotopic site. In short,
xenograft models of bone metastases have serious limita-
tions. Such issues are not unique to Kang and colleagues’
article; however, they are endemic to the field. It is impor-
tant to emphasize that such complications do not under-
mine their experiments, but point out the need for caution
when interpreting the data.
Metastasis genes that control colonization
In Kang and colleagues’ article, bone colonization was
affected in the transfectants while adrenal colonization
was not impacted by overexpression of these genes. This
implies that metastasis to each organ will be characterized
by different expression signatures. As a result, the concept
posited earlier regarding organotropism expression signa-
tures can be added to the hierarchy of array analysis.
The most common site of breast cancer metastasis is to
the bone. This observation was the crux of Paget’s seed
and soil hypothesis. In short, tumor cells (the seed) must
respond favorably to the tissue microenvironment (the soil)
in order to form overt metastases. At the core of Paget’s
hypothesis is the interaction between the tumor and the
host. This notion is nicely presented by Hunter and col-
leagues, who showed that a single oncogenic event could
lead to differential metastasis, depending upon the host
background [18,19].
Kang and colleagues showed that CXCR4, a chemokine
receptor for the SDF-1 ligand highly expressed in bone, is
more highly expressed in the 231-bone variant. Their find-
ings are consistent with clinical data in breast cancer [20].
The prevailing hypothesis is that tumor cells respond to
SDF-1 chemoattractant gradients to preferentially migrate
to bone. If this hypothesis were true, then bone over-
expressing SDF-1 would be more commonly colonized
than bone with low expression. To the best of my knowl-
edge, this hypothesis has not been directly tested.
Nonetheless, the cumulative data emphasize that DNA
expression is dependent, to some extent, upon exogenous
signals. Interestingly, many of the genes expressed in
231-bone are responsive to transforming growth factor
beta, which is prevalent in bone.
The conclusion that metastatic potential is determined by
early oncogenic events and not metastasis-specific genes
[5,6,8,9] is inconsistent with a growing literature demon-
strating the existence of genes that suppress metastasis
but that have no effect on tumorigenicity (reviewed in
[21,22]). Studies on metastasis-promoting genes, which
are the preferred targets for diagnostic studies, are com-
plicated by the requirement for coordinated expression of
multiple genes. As a result, false-negative results are more
likely when determining the function of metastasis-promot-
ing genes than the function of suppressors (since block-
ing any step inhibits metastasis) [23]. Studies designed to
explore promoting genes therefore generally start with a
baseline of metastasis and look for an increase. While
entirely appropriate based upon experimental considera-
tions, interpretation of experiments is not as straightfor-
ward as that for suppression.
Additionally, data are accumulating that some metastasis
suppressors may exert organ-specific effects (i.e. growth
of tumor cells is site specific). Goldberg and colleagues
showed, for example, that metastasis-suppressed
melanoma variants grow in the skin and disseminate to the
lung. Once in the lung, however, they remain quiescent for
extended periods [24]. Similarly, the Rinker-Schaeffer lab-
oratory has shown that the metastasis suppressor MKK4
exerts a similar growth suppression at the secondary site
while not affecting primary tumor growth [25,26]. In both
these studies, tumor cells complete every step of the
metastatic cascade except colonization. Both of these
examples support findings from the Chambers and Groom
laboratories showing high-frequency dissemination and
extravasation, but showing low-frequency proliferation at
the secondary site [27,28]. The cumulative data again
emphasize the necessity for coordinated expression of
genes to complete the entire metastatic process. It
remains unclear at this time whether the coordination of
gene expression is contemporaneous or sequential, syner-
gistic or additive, or even whether metastatic competence
is determined by unique or complementary pathways.
An unmistakable conclusion from the presented exam-
ples is that metastatic cells respond to environmental
signals differently to nonmetastatic cells. It is thus easy
to extrapolate that epigenetic regulation of some genes
is crucial to metastasis control. The only way to address
these complex issues will be to directly compare tran-
scriptomes and proteomes in matched primary tumors
and metastases (preferably from multiple sites)
microdissected from adjacent normal tissues. Even
then, until reliable and reproducible methods for single
cell analyses are at hand, there will remain questions
regarding interpretation.
In summary, the data by Kang and colleagues beautifully
highlight the multigenic nature of cancer metastasis and
show that some, but not all, cells in a primary tumor
express the entire cadre of genes necessary to colonize
bone. Their data, combined with that from many other lab-
oratories, supports the notion that specialized subpopula-
tions within the primary tumor can complete the metastatic
process. Their data also highlight the importance of arrays
for predicting clinical outcome, but emphasize the need
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